Litigation Details for Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2015)
✉ Email this page to a colleague
Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2015)
| Docket | ⤷ Try a Trial | Date Filed | 2015-04-27 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 7,645,459; 7,645,460; 8,246,989 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-06-26 | 36 | ABBREVIATIONS ’459 patent U.S. Patent Number 7,645,459 (DTX-2) ’460 patent U.S. Patent Number 7,…assert that two patents protect ATELVIA® from generic competition: U.S. Patent No. 7,645,459 (the “’459 … statutory infringement of U.S. Patent No. 7,645,459 (the “’459 patent”) pursuant to 35 U.S.C. § 271…459 patent”) and U.S. Patent No. 7,645,460 (the “’460 patent”). Both patents describe a delayed-release…the patent applications that led to the ’459 and ’460 patents had been published and the patents issued | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
